Compare Recursion Pharmaceuticals Inc (RXRX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs AT&T Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while AT&T Inc. trades at $24.49 (market cap $164.80B). The key difference: AT&T Inc. is far larger — about 92.6× Recursion Pharmaceuticals Inc's market cap, and AT&T Inc. pays a 4.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | T | |
|---|---|---|
Market Cap | $1.78B | $164.80B |
Sector | Health | Media |
52-Week High | $6.79 | $29.62 |
52-Week Low | $2.84 | $20.49 |
Enterprise Value | $1.30B | $310.12B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
AT&T (T) trades at $23.80, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.65 exceeding the $0.59 estimate. Revenue grew to $125.65 billion in 2025, and net income surged to $21.95 billion, reflecting a robust profit margin of 17.47%. Recent news highlights fiber expansion and 5G network investments.
The outlook is positive, supported by improving cash flow, strategic investments, and a 4.8% dividend yield. However, risks include competitive pressure from new entrants like SpaceX's Starlink and high debt levels. Analyst sentiment is mixed but leans bullish, with 41% buy ratings. The stock presents a value opportunity with a low P/E of 7.85, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
